Influenza Pipeline Insight 2025

Strategic Insights -

The global influenza pipeline landscape is a highly competitive space, with 120+ companies and 120+ pipeline drugs in development. DelveInsight's "Influenza Pipeline Insight 2025" report provides comprehensive insights into the pharmaceutical and biotechnology companies, therapies, and clinical trials involved in the development of treatments for influenza. The report highlights the key pipeline therapies, companies, and clinical trials making headlines in the industry.

Key Takeaways:

  • Eurofarma Laboratorios S.A. conducted a phase 3, multicenter, Randomized, Double-blind, comparative clinical trial to evaluate the association of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg in the flu and common cold treatment.
  • Sanofi Pasteur announced a study to provide sera to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.
  • DelveInsight's Influenza Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
  • Promising Influenza Therapies such as Fluviral[R], Varicella vaccine+TIV, Peramivir, Fluzone, Fluarix Tetra, VXA-A1.1, and others are being developed by companies like Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • The Influenza Pipeline report provides the therapeutic assessment of pipeline drugs by the Route of Administration, categorizing products into Inhalation, Inhalation/Intravenous/Oral, Intranasal, Intravenous, Intravenous/ Subcutaneous, NA, Oral, Oral/intranasal/subcutaneous, Parenteral, and Subcutaneous.
  • Influenza Products have been categorized under various Molecule types such as Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, and Vaccine.

Statistics:

  • 120+ companies are involved in the development of 120+ pipeline drugs for Influenza treatment.
  • 80+ clinical trials are being conducted to evaluate the safety and efficacy of pipeline therapies for Influenza treatment.
  • The Influenza Pipeline report covers 30+ emerging drug candidates, including mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, and ALVR106.
  • The global Influenza market is expected to grow at a CAGR of 12.5% from 2025 to 2030, driven by the increasing demand for effective treatments and vaccines.

Sources:

  • M2 PressWIRE, "Influenza Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight (C)1994-2025 M2 COMMUNICATIONS RDATE:17102025
  • DelveInsight's "Influenza Pipeline Insight 2025" report
  • About Us, DelveInsight